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ABSTRACT   
 
BACKGROUND: Unresolved questions remain concerning the 
protective effect and duration of immunity acquired from mothers. 
This study investigated persistence of immunity against tetanus in 
the first two weeks of life among neonates in Nigeria. 
METHODS: In a longitudinal study, 244 primiparous mothers and 
their newborns were consecutively recruited at 16 selected Primary 
Healthcare Centres in Ibadan, Nigeria. All the newborns were 
tested for protection against tetanus using a validated rapid 
diagnostic, “Tetanos Quick Sticks” (TQS) on days 1, 7 and 14. 
Persistent immunity was defined as positive TQS result on day-14. 
Data were analysed using descriptive statistics, Chi-square and 
logistic regression at p = 0.05. 
RESULTS: There were 137(56.1%) male neonates; 87.7% were 
delivered at ≥37weeks of gestation. The prevalence of protective 
immunity against tetanus (PIaT) among neonates on day-1 was 
63.5%; 119 out of 153 neonates remained positive to TQS test by 
day-14, giving a persistence rate of 77.8%. Independent predictors 
of persistent PIaT were residence in urban area (OR = 9.66; 95% 
CI = 2.42-38.45), maternal age (OR = 2.06; 95% CI = 1.49-2.85) 
and gestational age (OR = 1.84; 95% CI = 1.23-2.74).  
CONCLUSION: Protective immunity against tetanus waned in 
some neonates over the first two weeks of life, and this decline was 
inversely related to maternal and gestational ages. 
KEYWORDS:  Protective immunity, Primiparous women, 




Tetanus is one of the three leading causes of neonatal deaths in 
resource-limited countries worldwide. It contributes about 36% of 
deaths due to infections in this age group (1) and  killed 34,000 
newborns in 2015 alone (2).  The disease primarily affects skeletal 
muscles and manifests as “spasms and trismus” (3). Infection usually 
occurs through contaminated unhealed umbilical stump, particularly 
when the stump is cut with a non-sterile instrument. Infants who 
have acquired sufficient passive immunity from the mother are at 
low risk. Thus, it is possible to prevent neonatal tetanus through 
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vaccination, adoption of cheap and effective 
measures such as hand washing and the use of 
clean materials for treatment of the neonates’ 
umbilical stump. In 2016, approximately 96% 
reduction in mortality from neonatal tetanus was 
achieved through universal vaccination of 
pregnant mothers with tetanus toxoid which 
started in 1988 (2).  
Nigeria remains among 18 countries that still 
have not eliminated the disease in spite of the on-
going efforts to actively vaccinate pregnant 
women during antenatal care visits (2). Many 
Nigerian women seldom receive the recommended 
booster doses of tetanus toxoid after the routine 
immunisation in infancy (4). Even when the 
recommended two or more tetanus toxoid 
injections are given during pregnancy, the length 
of the protection offered by the tetanus vaccine in 
the neonates is not known. To this end, there have 
been reports of neonatal tetanus despite maternal 
vaccination during pregnancy (5). Therefore, the 
persistence of tetanus as a cause of morbidity and 
deaths among Nigerian children constitutes a 
matter of special concern. Most infants present 
with tetanus at about 8 to 14 days after birth, 
suggesting that the infection occurrs in the first 
week of life, but it is not known whether the 
immunity transferred from mother to foetus 
sufficiently lasts till 14 days after birth. It is 
therefore necessary to identify potential risk 
factors for non-protective immunity against 
tetanus in order to provide guides for making 
immediate decision to treat or take definitive steps 
towards prevention of tetanus in the newborn. 
 A recent publication showed that serological 
monitoring of immunity against tetanus is critical 
to maternal and neonatal tetanus elimination 
initiative in countries with high burden (6). 
However, it is apparent that such important 
information needed for policy review is lacking in 
Nigeria, in order to direct policy. Also, 
community-specific information is needed on 
factors that negatively impact on immunisation 
practices and its effectiveness in order to expedite 
tetanus eradication campaign in Nigeria. It was 
therefore necessary to investigate potential risk 
factors for non-protective immunity against 
tetanus among women and their neonates in 
Nigeria. This article presents the findings of the 
follow-up phase of a longitudinal study from 
which the baseline findings were earlier published 
(7). The aim of this aspect of the research was to 
find out whether protection offered by 
transplacentally-transferred antibodies against 
tetanus in neonates of primiparous mothers lasts 
till day-14. We also made attempt to address the 
question of whether neonates given anti-tetanus 
serum injection at birth have protective immunity 
by day 14 compared with those not given. 
METHODS 
 
Study design, study area and study setting: This 
research adopted a longitudinal design. Data were 
gathered for the same neonates repeatedly: within 
24 hours after birth, days 7 and 14 of neonatal life. 
The research was carried out in 16 Primary 
Healthcare Centres (PHC) located in Ibadan, 
Nigeria. These primary healthcare facilities were 
located within the communities and at readily 
accessible distances in order to serve as the first 
“point-of-call” for healthcare services. Ibadan has 
11 local governments areas (LGAs), made up of 
five within the metropolis and six at the periphery 
of the metropolis.  Officially, the five LGA within 
the metropolis are regarded as “urban LGAs” 
while those at the periphery of the metropolis are 
“rural LGAs” (8). As at the time of planning the 
study, 148 PHC were actively providing maternity 
services in the study area. Nurses/midwives and 
community health officers were responsible for 
day-to-day provision of healthcare at the PHCs 
level.  
Study population and sample size: This study 
focused on newborns of primiparous women who 
delivered their first pregnancy at any of the 
primary health and maternity centres located in the 
eight selected LGAs in Ibadan. The choice of this 
study population was based on an anecdotal 
observation by the researchers, which suggested 
that the majority of the cases of neonatal tetanus 
admitted at the University College Hospital were 
children of primiparous women (Unpublished 
data). Assuming the seroprevalence of non-
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protective immunity against tetanus as 50%, a 
minimum detectable difference of 10% between 
hypothesised and true value, we estimated that 196 
primiparous mothers would be required for the 
study at 95% level of confidence. This sample size 
was obtained using the formula for estimating 
minimum size for single proportion (9).  Since this 
study involved follow-up, it was anticipated that 
about 10% of the enrolled participants might be 
lost to follow-up or refuse follow-up data 
collection giving a minimum of 218 neonates 
required for the study.  
Sampling technique: The final sampling unit for 
this study was mother-baby pair.  A three-stage 
sampling technique was employed; to select local 
government areas (LGAs) in Ibadan, to select two 
primary health centres from the list of those 
providing maternity services in each LGA, and to 
consecutively recruit mothers and their newborns 
as they deliver in health centres on daily basis. 
Those who refused to provide informed consent, 
those who gave family history of allergy to any 
form of immunoglobulin and those who, in the 
judgement of the investigators, were not likely to 
comply with study protocol were not recruited. 
During the 20-month study period, there were 263 
livebirths given by primiparous women, but 244 
(92.8%) neonates participated in the study.  Of the 
244 mother-neonates pairs, four declined 
participation on day 14 of follow-up visits giving 
240 neonates.   
Data collection: All eligible primiparous mothers 
were asked to participate in the study within 24 
hours after delivery. Mothers’ consent was sought 
soon after they had verbally expressed their 
intention to participate in the study. Data were 
collected using an interviewer-administered semi-
structured questionnaire. The items in the 
questionnaire were adapted from those used for 
three previously published studies (10-12), and the 
questionnaire was described in an earlier 
publication (7).  The investigator and 16 trained-
nurses (assistants) collected data on day 1 on both 
mothers and neonates, and subsequently two times 
on days 7 and 14 on neonates only. A rapid 
diagnostic kit known as ‘Tetanos Quick Stick’ 
(TQS) (Gamma, Angleur, Belgium) was used to 
check for protection against tetanus as previously 
described (10). Also, anthropometry (weight, OFC 
and length) and physical examinations were 
carried out for neonates.   
Positive and negative TQS results were 
interpreted as Protective Immunity against 
Tetanus (PIaT) and Non-Protective Immunity 
against Tetanus (NPIaT), respectively. Persistent 
PIaT was defined as positive TQS result on day-14 
among those who had positive TQS results on 
day-1.  Neonates who tested negative to TQS on 
day 1 (that is NPIaT) were given human anti-
tetanus serum (ATS) immunisation injection 500 
IU (Vins Bioproducts Limited, India) once after a 
sensitivity test was carried out by injecting 0.1 ml 
serum in 1:10 dilution subcutaneously and 
observing for half an hour for any reactions of 
local or general.  
Data analysis: The main outcome variables 
measured were test results for TQS at birth (for 
mothers and neonates) and at 7 days as well as 14 
days after birth (for neonates only). A positive and 
negative tests were defined as protective and non-
protective tetanus immunity against tetanus, 
respectively. A positive and negative tests were 
defined as protective and non-protective tetanus 
immunity against tetanus, respectively. 
Independent variables measured included: 
demographic variables such as age, gender, socio-
economic class and obstetric history.  The family 
socio-economic background was determined using 
the classification proposed by Oyedeji (13).  
According to Oyedeji (13), socioeconomic index 
score was awarded based on the occupations and 
educational attainment of the neonate’s father and 
mother. In this study, average score of 1 was 
assigned class 1 (upper class), scores of 2 and 3 
were assigned class 2 (middle class) while scores 
of 4 and 5 were assigned class 3 (lower class). 
Chi-square test, Student’s t test and logistic 
regression analyses were performed. Level of 
statistical significance was set at p = 0.05. All data 
were analysed using SPSS for Windows 18.0 
(SPSS Inc., IL, USA).   
Ethical considerations: Participation in the study 
was completely voluntary and based on written 
informed consent.  The study proposal was 
reviewed and approved by the Oyo State Ethical 
Review Committee. Eligible mothers were 
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informed that they were free to withdraw their 
consent at any time. Neonates who tested negative 
to TQS received care according to standard 
protocol.  Privacy of research participants was 
ensured using a serial number on the information 
collected, rather than a name or hospital number. 
The results of TQS test in this study were made 
available to the health workers in their respective 
centres and the participants did not pay for any of 
the procedures and treatments. Mothers who did 
not have protective antitoxin were offered tetanus 




Characteristics of participants: The primiparous 
mothers’ age ranged from 20 to 33 years with a 
mean of 27.9±3.4 years. Some of the 
characteristics of the women, antenatal booking 
and immunisation status as well as the baseline 
characteristics of neonates were described in an 
earlier publication (7). All the four neonates 
who did not participate in the study on day 14 
were All the four neonates who did not 
participate in the study on day 14 were 
females, term and weighed 2600 to 3300 g. 
Only 8.2% of fathers and 7.4% of the mothers 
had at least university education, and 17.6% 
of the fathers and 27.0% of mothers of had no 
formal education. The most frequent 
occupational class was class III and class IV 
for the fathers and mothers, respectively. Of 
the 244 parents (fathers and mothers) who 
participated in the study, 64(26.2%) had the 
same levels of education while 46(18.9%) of 
the fathers and mothers were in the same 
occupational class.  
Table 1: Immunity against tetanus on Day 14 among 153 neonates who tested positive to TQS on Day 1  
 
 
Tetanus immunity in Neonates on 
Day 14 
OR (95% CI) P Not protected 
 
Protected 
n % n % 
Gender        
Female 21 32.3  44 67.7 2.75 (1.26, 6.04) 0.010 
Male* 13 14.8  75 85.2 1  
Gestational age category        
Preterm (<37 weeks) 14 70.0  6 30.0 13.18 (4.53, 38.36) <0.001 
Term (≥ 37 weeks)* 20 15.0  113 85.0 1  
Birthweight category (g)+        
≥2500 (Normal) 27 19.3  113 80.7 0.21 (0.06, 0.66) 0.004 
<2500 (Low)* 7  53.8  6 46.2 1  
Mothers’ place of residence        
Rural LGA 28 40.0  42 60.0 8.56 (3.28, 22.31) <0.001 
Urban LGA* 6 7.2  77 92.8 1  
 
*Reference category, OR = Odds Ratio (for being negative), CI = Confidence Interval;   
+All those in the <2500 g birth weight category were also Preterm (<37 weeks) 
 
Persistence of protective immunity against 
tetanus: At baseline, 155 were tested positive to 
TQS test, giving a seroprevalence of protective 
immunity against tetanus (PIaT) of 63.5%, as 
earlier reported (7). Table 1 shows that, among 
155 neonates who tested positive to TQS on day1, 
there were significant associations between 
immunity against tetanus on day 14 and gender, 
gestational age category, birthweight category and 
mothers’  residence. The prevalence and odds of 
PIaT on day 14 was significantly higher among 
males (85.2%) than females (67.7%); p = 0.010. 
Also, prevalence and odds of PIaT on day-14 was 
significantly higher among term (30.0%) more 
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than preterm (85.0%) neonates, those who 
weighed ≥2500 g (80.7%) than <2500 g (46.2%) 
and among neonates of mothers from urban 
(92.8%) than rural (60.0%) LGAs. However, there 
was no significant association between immunity 
against tetanus on day 14 and mothers’ level of 
education as shown in Table 2 (χ2 = 1.541; df = 4; 
p = 0.819). Similarly, there was no significant 
association between immunity against tetanus on 
day 14 and family social class as shown in Table 3 
(χ2 = 1.541; df = 4; p = 0.819). 
 
Table 2: Immunity against tetanus on Day 14 among 153 neonates who tested positive to TQS on Day 1 by 
mothers’ level of education 
 
Mothers’ Level of Education 
Tetanus immunity in Neonates 
on Day 14 
OR (95% CI) P Not 
protected  
Protected 
n % n % 
University graduates* 7 28.0  18 72.0 1 - 
Post-Secondary certificate not 
University 
3 21.4  11 78.6 0.70 (0.23, .50) 0.721 
Secondary School or Grade II certificate 8 18.6  35 81.4 0.59 (0.18, 1.88) 0.381 
Modern 3 and Primary 6 Certificate 8 19.0  34 81.0 0.61 (0.19, 1.94) 0.546 
No formal education 8 27.6  21 72.4 0.98 (0.30, 3.23) 0.786 
 *Reference category,   OR = Odds Ratio,  CI = Confidence Interval 
 
Table 3: Immunity against tetanus on Day 14 among 153 neonates who tested positive to TQS on day 
family social class 
 
Family Social Class 
Tetanus immunity in Neonates on Day 14 
OR (95% CI) P Not protected 
 
Protected 
n % n % 
I (Highest) 0 0.0  0 0.0 - - 
II* 3 37.5  5 62.5 1 - 
III 15 27.8  39 72.2 0.64 (0.14, 3.02) 0.681 
IV 12 18.2  54 81.8 0.37 (0.08, 1.77) 0.347 
V (Lowest) 4 16.0  21 84.0 0.32 (0.05, 1.90)  
 
 *Reference category,   OR = Odds Ratio,  CI = Confidence Interval 
 
 
Predictive factors for persistence of protective 
immunity against tetanus: Table 4 shows the 
estimates for the predictor-model to identify 
independent predictors for PIaT on day 7 among 
neonates. Maternal age (p<0.0001), mothers’  
residence (p < 0.0001) and administration of 2 
doses of tetanus toxoid injection (p = 0.021) were 
the important independent predictors of PIaT on 
day 7. Since maternal age and gestational age are 
numerical variables, an increase in one year in 
maternal age has a 118% (95% CI 50% to 217%) 
increase in odds of having PIaT on day 7. A 
neonate of mothers from urban compared to a 
rural LGA is 6.82 (95% CI = 3.81 to 8.13) times 
more likely to have PIaT on day 7.  However, the 
Nagelkerke R Square (0.864) shows that about 
86.4% of the variation in the immunity against 
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Table 4: Predictive factors for persistence of protective immunity against tetanus till Day 7 among neonates 
who tested positive on Day 1 
 
 B S.E. Wald df p OR 95% CI for OR 
Maternal age in years 0.78 0.19 16.66 1 <0.0001 2.18 1.50, 3.17 
Mothers’ place of residence (Urban)1 1.92 1.18 12.91 1 <0.0001 6.82 3.81, 8.13 
Gestational age in weeks 0.15 0.29 0.27 1 0.601 1.17 0.66, 2.07 
Mothers received 2 doses of tetanus 
toxoid injection (Yes)2 
1.25 1.54 5.35 1 0.021 3.48 1.72, 7.06 
Birthweight (≥2500 g)3 1.09 1.55 0.49 1 0.483 2.97 0.14, 6.22 
Neonate’s gender (female)4 1.03 1.44 0.51 1 0.472 2.81 0.17, 4.78 
Constant -
31.03 
14.3 4.72 1 0.030 0.00 - 
Reference categories:  1Rural LGA 2No  3Birthweight <2500 g   4Neonate’s gender (Male) 
Wald estimates give the “importance” of the contribution of each variable in the model 
 
The estimates for the predictor-model to identify 
independent predictors for PIaT on day 14 among 
neonates were as shown in Table 5. Maternal age 
(p<0.0001), mothers’  residence (p = 0.001) and 
gestational age in weeks (p = 0.003) were the 
important independent predictors for PIaT on day 
14. Since maternal age and gestational age are 
numerical variables, an increase in one year in 
maternal age and one week in gestational age has 
a 106% (95% CI 49% to 185%) and 84% (95% CI 
23% to 174%) increase in odds of having PIaT on 
day-14, respectively. A neonate of mothers from 
urban compared to a rural LGA is 9.7(95% CI 
2.43 to 38.45) times more likely to have PIaT on 
day14. However, the Nagelkerke R Square (0.664) 
suggests that about 66.4% of the variation in the 
immunity against tetanus on day 14 is explained 
by this logistic model. 
DISCUSSION 
 
This study revealed that persistence rate of 
protective immunity against tetanus till day 7 and 
day 14 was moderately high. Only a few neonates 
(17.4%) who had protective immunity against 
tetanus lost it by day 7.  Female gender, residence 
in rural local government areas and low birth 
weight were risk factors for non-protective 
immunity against tetanus among neonates of 
primiparous mothers on day 14. The fact that lack 
of protection against tetanus could still occur 
among newborns of women who were vaccinated 
and that those who acquired immunity may lose it 
within 7-14 days should prompt health workers to 
continue to pay attention to identified risk factors. 
This aspect of clinical practice is critical, in order 
to provide guides for making immediate decision 
to treat or take definitive steps towards prevention 
of tetanus in the newborn. 
Prior to the conduct of this study, to our 
knowledge, the roles of gender of neonates and 
place of residence in determining the level of 
immunity against tetanus in neonatal age group 
were not found in literature. Though reasons for 
the significant gender difference in non-protective 
immunity against tetanus are not clear from our 
data, it is likely that the gender difference 
observed may have resulted from differences in 
immunisation status of mothers in the two groups. 
However, this reason was not further explored. On 
the contrary, the higher prevalence of non-
protective immunity on day 14 among neonates 
who had protective immunity on day 1 in rural 
area (40.0%) than urban (7.2%) area was 
expected. This finding corroborates the fact that 
the tetanus immunisation coverage among mothers 
was also poorer in the same area as shown in our 
data.  
The identification of low birth weight as a risk 
factor for lack of persistence in the maternally 
acquired immunity till day 14 of life  may be 
partly explained by the fact that all the neonates 
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who were in this category were delivered before 
term.  Studies have shown that the immunised 
mother transfer antibodies against tetanus across 
the placenta to the foetus in form IgG antibodies 
(14,15). 
 This is expected to provide passive 
protection of the newborn against tetanus in the 
first two weeks, but gradually wanes over time. 
However, the influences of the timing of 
vaccination, history of previous tetanus 
vaccination and maternal biological characteristics 
such as immune status on the attainment of 
protective level of immunity in the newborn are 
unclear from this data. Nevertheless, all the 
neonates who tested negative to TQS and were 
given the ATS injection remained protected 
against tetanus beyond day 7 of the follow-up.  
Within the limit of the study design, our data 
defined potential maternal and newborn risk 
factors for low tetanus immunity. This information 
can assist healthcare providers in objectively 
deciding who should be given the ATS injection 
before discharge from the delivery centres. The 
much desired evidence to support the continued 
use of ATS injections for the purpose of protecting 
neonates whose mothers received less than two 
doses or no tetanus toxoid injection before the 
third trimester in pregnancy has been corroborated 
by our findings. Also, we have provided more 
information on the possibility of utilising the 
validated Immunochromatographic Rapid 
Diagnostic Test (IRDT) kit for testing protection 
against tetanus in mothers and neonates, especially 
in the first 14 days of life.  
Our data are unique in that, within the limits 
of accessible literature, it appears to be the first 
attempt at investigating the persistence of 
immunity against tetanus in Nigerian neonates. 
We have brought to the fore the importance of 
socio-demographic characteristics in guiding 
tetanus immunisation policy. For instance, it is 
now clear that efforts towards the attainment of 
the WHO-recommended 80% coverage among 
pregnant women need to be scaled up in the rural 
areas in Nigeria. However, it is important to 
identify the reasons why neonates continued to 
present with tetanus in the hospital despite routine 
maternal vaccination which could not be explained 
from our data. At a time when the global focus has 
shifted to curbing neonatal mortality, it is fitting 
that research be intensified into the prevention of 
mortality among neonates.  
There are two points which validate and 
support the generalisability of our data. First, this 
study included preterm and term neonates, and the 
percentage of neonates lost to follow-up was 
considerably lower than the 10% allowed for in 
the study design. Second, we chose a 
representative sample of the study area, across all 
socio-economic strata, and we used validated 
instrument and test kit to check for protection 
against tetanus immunity. However, it remains 
unknown whether detection of maternally 
acquired antibody against tetanus can be 
determined beyond day 14 in Nigeria neonates. It 
is worthy of note that previous studies alluded to 
the fact that HIV might be playing important roles 
in the transfer of antibodies against tetanus from 
mothers to foetus (16,17). Though attempts were 
made to find out about the HIV status during 
pregnancy, only four mothers could provide proof 
of being seronegative to HIV test. It was 
practically impossible to assess the impact of HIV 
infection on the protective immunity against 
tetanus among the cohort of women who took part 
in the study.  
In conclusion, immunity against tetanus 
among neonates of primiparous women in Ibadan 
waned in some neonates within two weeks of life. 
Health workers should be aware of risk factors 
associated with declining immunity and continue 
to consider administration of tetanus 
immunoglobulin to neonates whose mothers did 
not receive complete tetanus toxoid injections 
during pregnancy. A more conscientious 
enforcement of routine tetanus prevention 
practices is recommended, especially in the rural 
areas and for neonates with low birth weight and 
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